RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BORELLI B
Collezione AOU Città della Salute di Torino

Items : 7

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Aug 1;42(22):2637-2644. doi: 10.1200/JCO.23.02728. Epub 2024 Jun 12.

2024
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C;

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27.

2022
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; et alii...

CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies. in British journal of cancer / Br J Cancer. 2021 Sep;125(6):839-845. doi: 10.1038/s41416-021-01483-x. Epub 2021 Jul 12.

2021
AOU Città della Salute di Torino

Cupini S; Fanchini L; Buonadonna A; Ambrosini M; Zaniboni A; Zucchelli G; Caponnetto S; Borelli B; Tomasello G; Marmorino F; Santini D; Antoniotti C; Rasola C; Lonardi S; Conca V; Rossini D; Moretto R; Masi G; Falcone A; Cremolini C;

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. in BMC cancer / BMC Cancer. 2020 Jul 22;20(1):683. doi: 10.1186/s12885-020-07169-6.

2020
AOU Città della Salute di Torino

Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C;

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. in British journal of cancer / Br J Cancer. 2020 Aug;123(3):403-409. doi: 10.1038/s41416-020-0894-7. Epub 2020 May 19.

2020
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Tonini G; Adamo V; Loupakis F; Tomasello G; Zaniboni A; Murialdo R; Boccaccino A; Claravezza M; Bustreo S; Tampellini M; Borelli B; Sartore-Bianchi A; Rimassa L; Lonardi S; Marmorino F; Corallo S; Moretto R; Morano F; Antoniotti C; Guarini V; Fucà G; Cortesi E; de Braud F; Cremolini C; Pietrantonio F; Fucà G; Guarini V; Antoniotti C; Morano F; et alii...

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. in The oncologist / Oncologist. 2019 Oct;24(10):1395-1402. doi: 10.1634/theoncologist.2018-0785. Epub 2019 Apr 5.

2019
AOU Città della Salute di Torino

Bardelli A; Zagonel V; Marrapese G; Ciardiello F; Vaghi C; Martino C; Bonoldi E; Valtorta E; Racca P; Tosi F; Borelli B; Martinelli E; Bergamo F; Fenocchio E; Leone F; Lonardi S; Ghezzi S; Amatu A; Porcu L; Sartore-Bianchi A; Trusolino L; Torri V; Marsoni S; Siena S;

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. in Oncotarget / Oncotarget. 2017 Dec 21;9(8):7859-7866. doi: 10.18632/oncotarget.23559. eCollection 2018 Jan 30.

2018
AO Cuneo
AOU Città della Salute di Torino

Danesi R; Falcone A; Boni L; Zagonel V; Di Donato S; Buonadonna A; Allegrini G; Ricci V; Racca P; Ronzoni M; Tomasello G; Zaniboni A; Moretto R; Cortesi E; Citi V; Marmorino F; Borelli B; Loupakis F; Bergamo F; Antoniotti C; Lonardi S; Del Re M; Cremolini C;